Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry-Reference-Cited by-同舟云学术

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

Published:2023-10 Issue:4 Volume:62 Page:106952
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Salmanton-García Jon^ORCID,Marchesi Francesco^ORCID,Koehler Philipp,Weinbergerová Barbora,Čolović Natasa,Falces-Romero Iker^ORCID,Buquicchio Caterina,Farina Francesca,van Praet Jens^ORCID,Biernat Monika M.,Itri Federico,Prezioso Lucia,Tascini Carlo,Vena Antonio^ORCID,Romano Alessandra,Delia Mario,Dávila-Valls Julio,Martín-Pérez Sonia,Lavilla-Rubira Esperanza,Adžić-vukičević Tatjana,García-Bordallo Daniel^ORCID,López-García Alberto,Criscuolo Mariana,Petzer Verena,Fracchiolla Nicola S.^ORCID,Espigado Ildefonso,Sili Uluhan^ORCID,Meers Stef,Erben Nurettin,Cattaneo Chiara,Tragiannidis Athanasios,Gavriilaki Eleni,Schönlein Martin^ORCID,Mitrovic Mirjana,Pantic Nikola^ORCID,Merelli Maria^ORCID,Labrador Jorge^ORCID,Hernández-Rivas José-Ángel,Glenthøj Andreas,Fouquet Guillemette^ORCID,del Principe Maria Ilaria,Dargenio Michelina,Calbacho María^ORCID,Besson Caroline^ORCID,Kohn Milena,Gräfe Stefanie,Hersby Ditte Stampe,Arellano Elena,Çolak Gökçe Melis^ORCID,Wolf Dominik,Marchetti Monia^ORCID,Nordlander Anna,Blennow Ola^ORCID,Cordoba Raul,Mišković Bojana^ORCID,Mladenović Miloš^ORCID,Bavastro Martina,Limongelli Alessandro^ORCID,Rahimli Laman,Pagano Livio,Cornely Oliver A.^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference40 articles.

1. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction;Mahase;BMJ,2020

2. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021

3. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

4. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial;Gottlieb;JAMA,2021

5. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial;Lancet Respir Med,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study;Journal of Pharmaceutical Health Care and Sciences;2024-09-03

2. Carga de la COVID-19 variante ómicron en pacientes inmunocomprometidos en España: revisión sistemática;Medicina Clínica;2024-06

3. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022;eClinicalMedicine;2024-05

4. Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients;Cancers;2024-03-05

5. Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence;Infectious Disease Reports;2023-10-25